Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2002

View Archived Issues

Potential role for CEP-701 in the treatment of acute myeloid leukemia

Rats expressing DPP-IV show improved glycemic control after treatment with NVP-DPP-728

Cognitive and behavioral improvements on donepezil in comorbid schizophrenia and dementia

Patient enrollment completed for phase III clinical trial with Tarceva

Xechem acquires exclusive worldwide rights to Niprisan

Collaboration agreement announced for the development of emphysema treatment

AVI-4126 completes phase Ib polycystic kidney disease trial

Forest submits memantine NDA for Alzheimer's disease

Aventis and ViroPharma terminate Picovir agreement

Biomira updates recent progress of Theratope and BLP25

Modex advances Allox through early-stage clinical testing

Novel anti-HIV agents presented by AIDS Care Pharma

New vasopressin V1a/V2 modulators for renal failure and hypertension

Novel prostaglandin D2 antagonists included in Merck Frosst patent

Merck & Co. researchers identify new alphavbeta3/alphavbeta5 integrin antagonists

Novel NPY5 modulators in early development at Neurogen

New antiarrhythmic Kv1.5 channel blockers prepared and tested at Aventis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...